共 172 条
[1]
Lin NU(2008)Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases Cancer. 113 2638-2645
[2]
Claus E(2007)Central nervous system metastases in HER-2–positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors Oncologist 12 766-773
[3]
Sohl J(2016)A Multidisciplinary breast cancer brain metastases clinic: the University of North Carolina Experience Oncologist. 21 16-20
[4]
Razzak AR(2017)Outcomes from 735 patients with breast cancer brain metastases (BM) according to biological subtype, number of BMs, and systemic treatment after local therapy J Clin Oncol 35 2078-948
[5]
Arnaout A(2010)Breast cancer brain metastases: differences in survival depending on biological subtype, RPA RTOG prognostic class and systemic treatment after whole-brain radiotherapy (WBRT) Ann Oncol 21 942-37
[6]
Winer EP(2018)Changing natural history of HER2-positive breast cancer metastatic to the brain in the era of new targeted therapies Clin Breast Cancer 18 29-1142
[7]
Gori S(2019)Upfront brain radiotherapy may improve survival for unfavorable prognostic breast cancer brain metastasis patients with Breast‐GPA 0‐2.0 The Breast Journal 25 1134-1356
[8]
Rimondini S(2017)Overall survival with combined nivolumab and ipilimumab in advanced melanoma N Engl J Med 377 1345-1639
[9]
De Angelis V(2015)Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer N Engl J Med 373 1627-2121
[10]
Colozza M(2019)Checkpoint blockade strategies in the treatment of breast cancer: where we are and where we are heading Curr Treat Options in Oncol 20 35-803